Equillium: The Market Seems To Have Already Priced In Phase 1 Success
Equillium Inc EQ
$2.20
▼ -5.17%
($-0.12)
🗓️ Earnings Next Week
Open
$2.31
Prev Close
$2.32
Day Range
$2.18 – $2.37
52W Range
$0.37 – $3.54
Market Cap
$139.10M
Beta
1.86
EPS (TTM)
$-0.32
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-10-12 |
| Shares Out. | 63,230,000 |
| Website | equilliumbio.com/home/default.aspx ↗ |
| Phone | 18009279800 |
| Employees | 14 |
| Net Income | -$5.3M |
| Free Cash Flow | -$18.9M |
| Total Assets | $63.1M |
| Total Liabilities | $3.6M |
| Equity | $59.5M |
About Equillium Inc
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
Equillium Inc is a publicly traded company under the ticker symbol EQ on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-07-01)